Immatics

Immatics Forward P/E

The Forward P/E Ratio of Immatics (IMTX) as of Nov 19, 2026 is -5.67. In the previous year, Forward P/E Ratio was 73.16 — a change of -107.75% (lower).

Forward P/E

-5.67

YoY

-107.75%

Last updated:

Forward P/E Ratio of Immatics is 2025 -5.67 . Forward P/E Ratio of Immatics was 2024 73.16 . It decreases by -107.75% lower compared to the previous year.

The Immatics Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-35.41 EUR
Jan 1, 2019
-35.26 EUR
Jan 1, 2020
-4.86 EUR
Jan 1, 2021
-11.93 EUR
Jan 1, 2022
29.68 EUR
Jan 1, 2023
-11.76 EUR
Jan 1, 2024
73.16 EUR
Jan 1, 2025
-5.67 EUR
The Immatics Forward P/E history
YEARForward P/EYoY
-5.67-107.75%
73.16-721.95%
-11.76-139.63%
29.68-348.80%
-11.93+145.42%
-4.86-86.22%
-35.26-0.40%
-35.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immatics Stock analysis

What does Immatics do? Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors through Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). The company's pipeline includes eight therapeutic programs, with four in clinical trials: IMA201 (MAGEA4/8), IMA202 (MAGEA1), ACTolog IMA 101 (Multi-target pilot trial), and IMA203 (PRAME). Four programs are in preclinical development, such as IMA204 (COL6A3) and IMA401 (Cancer testis antigen). Immatics generates revenue through licensing agreements and potential future sales of its therapies, targeting pharmaceutical companies and research institutions seeking advanced cancer treatments. The company's clinical-stage therapies are designed to enable robust T-cell responses against cancer targets, with programs like IMA201 and IMA202 focused on solid tumors. IMA203 addresses both hematological and solid cancers, while preclinical programs like IMA401 and IMA402 target cancer testis antigens. Immatics partners with biopharmaceutical firms to advance its pipeline, leveraging its TCR technology platform to develop therapies for unmet medical needs in oncology. Immatics' revenue model relies on strategic partnerships and licensing deals with pharmaceutical companies, which fund clinical development and gain access to its proprietary TCR platform. The firm's focus on solid tumors and hematological cancers attracts interest from major biopharmaceutical players looking to expand their oncology portfolios. Through its eight therapeutic programs, Immatics aims to deliver innovative treatments that address high unmet medical needs in cancer therapy. Immatics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immatics stock

Forward P/E Ratio of Immatics is -5.67 in 2025.

Forward P/E Ratio of Immatics changed from 73.16 to -5.67, representing a -107.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Immatics since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Immatics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Immatics

All Key Metrics — Immatics